2023
Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults
Kopel H, Nguyen V, Boileau C, Bogdanov A, Winer I, Ducruet T, Zeng N, Bonafede M, Esposito D, Martin D, Rosen A, Van de Velde N, Vermund S, Gravenstein S, Mansi J. Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults. Vaccines 2023, 11: 1711. PMID: 38006043, PMCID: PMC10675676, DOI: 10.3390/vaccines11111711.Peer-Reviewed Original ResearchCOVID-19-related hospitalizationRelative vaccine effectivenessOutpatient visitsPrimary care electronic health recordsCOVID-19-related outcomesVaccine-induced protectionMedical claims dataCOVID-19 vaccineSARS-CoV-2Electronic health recordsVaccine effectivenessVaccine recipientsMRNA vaccinesBivalent vaccineBaseline differencesStudy populationClaims dataOmicron variantComparative effectivenessHospitalizationPropensity scoreVaccineOlder adultsHealth recordsVisits
2016
Higher Prevalence of Human Papillomavirus-Related Cervical Precancerous Abnormalities in HIV-Infected Compared to HIV-Uninfected Women
Choudhury SA, Choudhury NA, Humphrey AD, Berthaud V, Ladson G, Tucker VA, Vermund SH. Higher Prevalence of Human Papillomavirus-Related Cervical Precancerous Abnormalities in HIV-Infected Compared to HIV-Uninfected Women. Journal Of The National Medical Association 2016, 108: 19-23. PMID: 26928484, PMCID: PMC10767705, DOI: 10.1016/j.jnma.2015.12.003.Peer-Reviewed Original ResearchConceptsHigh-risk human papillomavirusNon-Hispanic African American womenNon-Hispanic white womenAfrican American womenPrecancerous lesionsHPV vaccinationHuman papillomavirusMedical recordsHispanic womenPrevalence of HPVPersistent high-risk human papillomavirusWhite womenHIV uninfected groupHIV uninfected womenRoutine HPV vaccinationHPV vaccination ratesRisk human papillomavirusCervical precancerous lesionsAmerican womenHIV-InfectedPrecancerous abnormalitiesUninfected womenHPV vaccineVaccine recipientsCervical abnormalities
1998
Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines
Connor RI, Korber B, Graham BS, Hahn BH, Ho DD, Walker BD, Neumann AU, Vermund SH, Mestecky J, Jackson S, Fenamore E, Cao Y, Gao F, Kalams S, Kunstman KJ, McDonald D, McWilliams N, Trkola A, Moore JP, Wolinsky SM. Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines. Journal Of Virology 1998, 72: 1552-1576. PMID: 9445059, PMCID: PMC124637, DOI: 10.1128/jvi.72.2.1552-1576.1998.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus type 1Immunodeficiency virus type 1Virus type 1MN rgp120Antibody responseHIV-1Recombinant gp120 subunit vaccinePhase I/II clinical trialsCytotoxic T lymphocyte responsesType 1Immunoglobulin G antibody responseGp120 subunit vaccineSyncytium-inducing (SI) phenotypeT lymphocyte responsesG antibody responseClade B virusesInducing (NSI) phenotypeInfected vaccineesNSI strainsPlacebo recipientsVaccine recipientsViral burdenPlacebo vaccineAntibody titersMultiple immunizationsAnalysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines
Graham B, McElrath M, Connor R, Schwartz D, Gorse G, Keefer M, Mulligan M, Matthews T, Wolinsky S, Montefiori D, Vermund S, Lambert J, Corey L, Belshe R, Dolin R, Wright P, Korber B, Wolff M, Fast P, Group A. Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines. The Journal Of Infectious Diseases 1998, 177: 310-309. PMID: 9466516, DOI: 10.1086/514209.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS VaccinesAmino Acid SequenceCD4 Lymphocyte CountFemaleHIV AntibodiesHIV Envelope Protein gp120HIV InfectionsHIV-1HumansImmunity, ActiveIncidenceMaleMiddle AgedMolecular Sequence DataNeutralization TestsPeptide FragmentsRisk-TakingSequence AnalysisSubstance Abuse, IntravenousViral LoadConceptsHIV-1 infectionHuman immunodeficiency virus type 1 (HIV-1) infectionVirus type 1 infectionCandidate AIDS vaccinesType 1 infectionAIDS vaccinePhase IHigh-risk sexual exposureVaccine-induced immune responsesComplete immunization scheduleEarly clinical courseCD4 lymphocyte countIntravenous drug useV3 loop amino acid sequencesUninfected subjectsVaccine recipientsLymphocyte countClinical courseImmunization scheduleSexual exposureVirus loadImmune responseControl groupDrug useInfection